Gastrinoma Medical Services in China

Gastrinoma is a rare, neuroendocrine tumor that secretes excessive amounts of gastrin—typically arising from the duodenum (60–70%) or pancreas (20–30%), and less commonly from gastric, jejunal, or lymph node tissue. It is the principal cause of Zollinger–Ellison syndrome (ZES), characterized by profound gastric acid hypersecretion, recurrent peptic ulcer disease, gastroesophageal reflux, diarrhea, and malabsorption. Pathogenically, gastrinomas originate from enterochromaffin-like (ECL) cells or gastrin-producing G-cells in the antrum or duodenal Brunner’s glands. Most sporadic cases involve somatic mutations in genes such as MEN1, CDKN1B, or DAXX/ATRX; approximately 20–25% occur in the context of multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder with germline MEN1 gene mutations. Tumor behavior varies: while ~60–70% are malignant at diagnosis (with hepatic or lymph node metastases), duodenal tumors tend to be smaller and less aggressive than pancreatic ones. Epidemiologically, gastrinoma incidence is estimated at 0.5–2 cases per million person-years, with a median age at diagnosis of 50–60 years and slight male predominance (M:F ≈ 1.5:1). Risk factors include familial MEN1 syndrome, prior gastric surgery (e.g., vagotomy), chronic atrophic gastritis, and possibly long-standing proton pump inhibitor (PPI) use—though causality remains unproven. Diagnosis hinges on elevated fasting serum gastrin (>1000 pg/mL), gastric acid hypersecretion (basal acid output >15 mEq/h), and provocative testing (e.g., secretin stimulation test); imaging (EUS, SRS, Ga-68 DOTATATE PET/CT) localizes tumors. Untreated, gastrinoma significantly impairs quality of life: chronic abdominal pain, debilitating diarrhea, weight loss, nutritional deficiencies (e.g., iron, B12, calcium), fatigue, and anxiety related to recurrent ulcers or cancer progression are common. Even with treatment, lifelong PPI therapy is often required, and patients face surveillance burdens, surgical morbidity, and psychosocial stress—including concerns about malignancy, hereditary risk for family members, and limitations in diet, travel, and work due to GI instability. Early detection and multidisciplinary management (endocrinology, gastroenterology, oncology, surgery) markedly improve outcomes and functional status.

Gastrinoma is a rare, neuroendocrine tumor (NET) that secretes excessive gastrin, leading to Zollinger–Ellison syndrome (ZES). It most commonly arises in the duodenum (60–70%) or pancreas (20–30%), with occasional ectopic origins. Gastrinomas are often malignant—approximately 60–70% exhibit lymph node or hepatic metastases at diagnosis—and approximately 25% occur sporadically, while the remainder are associated with multiple endocrine neoplasia type 1 (MEN1). Management requires a multidisciplinary approach coordinated by endocrinology, gastroenterology, surgical oncology, nuclear medicine, and pathology.

Conservative treatment is indicated for patients with unresectable, metastatic, or asymptomatic disease, particularly those with indolent tumor biology or significant comorbidities precluding surgery. The cornerstone of conservative management is gastric acid suppression using high-dose proton pump inhibitors (PPIs), such as esomeprazole (40–120 mg twice daily) or pantoprazole (80–240 mg daily), titrated to maintain basal gastric pH >4 and resolve symptoms (e.g., refractory peptic ulcer disease, diarrhea, gastroesophageal reflux). PPI therapy does not inhibit tumor growth but prevents life-threatening complications including ulcer perforation, hemorrhage, and strictures. Long-term PPI use necessitates monitoring for hypomagnesemia, vitamin B12 deficiency, and potential rebound hypergastrinemia; however, elevated serum gastrin in this context reflects pharmacologic inhibition—not tumor progression—and must be interpreted cautiously. Endoscopic surveillance every 1–2 years is recommended to detect mucosal complications. In select cases with stable, low-volume liver metastases, active surveillance with serial imaging (MRI or contrast-enhanced CT) and chromogranin A/gastrin levels every 3–6 months may be appropriate.

Pharmacotherapy extends beyond acid suppression. Somatostatin analogues (SSAs)—octreotide LAR (20–30 mg intramuscularly every 4 weeks) or lanreotide Autogel (90–120 mg subcutaneously monthly)—are first-line systemic agents for symptomatic control and antiproliferative activity in well-differentiated, somatostatin receptor–positive (SSTR+) gastrinomas. SSAs reduce gastrin secretion, alleviate diarrhea, and stabilize tumor growth in ~60–70% of patients. Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE is FDA- and NMPA-approved for progressive, SSTR-positive G1/G2 NETs—including gastrinoma—and demonstrates objective response rates of 15–30%, prolonged progression-free survival (median ~28 months), and improved quality of life. For higher-grade (G3) or PRRT-ineligible tumors, cytotoxic chemotherapy (e.g., capecitabine/temozolomide) or targeted agents (everolimus, sunitinib) may be considered based on molecular profiling and tumor grade. Molecular testing—including MEN1 germline sequencing—is mandatory in all newly diagnosed patients to guide genetic counseling and screening of relatives.

Surgical resection remains the only potentially curative intervention and is strongly recommended for localized, resectable gastrinomas without distant metastases. En bloc resection with regional lymphadenectomy is standard: pancreatic head tumors require Whipple procedure; duodenal tumors necessitate segmental duodenectomy with ampullary preservation when feasible; and small, superficial duodenal lesions may be excised endoscopically or via laparoscopic wedge resection. Preoperative localization is critical and typically involves dual-phase contrast-enhanced CT/MRI, endoscopic ultrasound (EUS), and ⁶⁸Ga-DOTATATE PET/CT—which offers superior sensitivity (>90%) and specificity for primary and metastatic disease. In MEN1-associated gastrinoma, surgery is more nuanced: duodenal microgastrinomas are nearly universal, and prophylactic pancreaticoduodenectomy is not advised due to high morbidity; instead, selective resection of dominant lesions ≥1 cm with nodal sampling is preferred. Complete resection (R0) correlates with 10-year survival exceeding 90%, whereas R1/R2 resection or unresectable disease reduces 10-year survival to 40–60%.

China offers distinct advantages in gastrinoma management. First, advanced multimodal imaging—including widespread access to ⁶⁸Ga-DOTATATE PET/CT and high-resolution EUS—is increasingly available in tier-1 and tier-2 hospitals, enabling precise staging. Second, China’s National Medical Products Administration (NMPA) has expedited approvals for key therapeutics: ¹⁷⁷Lu-DOTATATE received conditional approval in 2022, and generic octreotide LAR and lanreotide are widely accessible at lower cost than in Western markets. Third, specialized NET centers—such as those at Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—employ integrated tumor boards with standardized protocols aligned with ENETS and NANETS guidelines. Fourth, China’s large patient volume supports robust clinical trial participation, including investigator-initiated studies on novel SSA formulations and combination therapies. Finally, centralized pathology review through national NET reference networks ensures accurate grading (Ki-67 index, mitotic count) and immunohistochemical profiling (chromogranin A, synaptophysin, SSTR2), minimizing diagnostic variability.

Post-treatment recovery emphasizes long-term surveillance and lifestyle adaptation. Patients require lifelong follow-up: fasting serum gastrin, chromogranin A, and liver function tests every 3–6 months for the first 3 years, then annually if stable; abdominal MRI or CT every 6–12 months; and ⁶⁸Ga-DOTATATE PET/CT every 1–2 years for high-risk or metastatic cases. Dietary counseling should emphasize small, frequent meals; avoidance of caffeine, alcohol, and NSAIDs; and calcium/vitamin D supplementation if on chronic PPIs. Psychological support is essential—patients often experience anxiety related to cancer recurrence and chronic symptom burden. Genetic counseling is mandatory for all patients and first-degree relatives in suspected MEN1 cases. Smoking cessation is strongly advised, as tobacco use accelerates NET progression. Finally, patients should be educated to recognize red-flag symptoms—including hematemesis, melena, severe abdominal pain, or new-onset jaundice—and seek urgent evaluation. With comprehensive, individualized care spanning medical, surgical, and supportive domains, gastrinoma outcomes continue to improve globally—and China’s rapidly evolving infrastructure positions it as a leader in accessible, evidence-based NET management.